FinTech
Cynata Therapeutics: Receives approval for acute graft-versus-host disease clinical trial
Cynata Therapeutics Receives approval for acute graft-versus-host disease clinical trialCynata Therapeutics (CYP) receives approval to launch a phase two clinical trial in acute...
FinTech
Cynata Therapeutics: Welcomes tax incentive refund
Biotechnology company Cynata Therapeutics (CYP) has received a research and development (R&D) tax incentive refund of over $1.3 million
The R&D tax incentive...
FinTech
Cynata Therapeutics: Announces positive efficacy data from lung disease study
Biotech Cynata Therapeutics has announced positive efficacy data from a Cymerus mesenchymal stem cell study in rodents with IPF
IPF, idiopathic pulmonary fibrosis,...
FinTech
Cynata Therapeutics: Receives an extra $618k R&D tax refund
Cynata Therapeutics: Receives an extra $618k R&D tax refundCynata Therapeutics (CYP) has received a $618,667 research and development (R&D) tax refund for the...
Banking
Cynata Therapeutics: Receives R&D tax incentive refund of more than $1.8M
Cynata Therapeutics: Receives R&D tax incentive refund of more than $1.8MCynata Therapeutics received a research and development tax incentive refund of $1,891,795 for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read